BERG’s Interrogative Biology® platform identifies novel disease drivers and actionable targets. The preclinical and drug discovery programs that follow are focused on using fragment-based ligand discovery campaigns to identify hit fragments. Using a combination of structure-guided drug design and pharmacophore-based approach, the team develops lead molecules that are subjected to proof of concept studies in appropriate in vivo models, extensive optimization for metabolism, pharmacokinetics, and elimination of toxicophoric liabilities. The use of the fragment-based discovery has enabled efficient hit to lead programs for novel targets that were hitherto considered to be not druggable.